Open Access Drug Development Tools Feature in New IMI Call for Proposals

Innovative Medicines InitiativeNew open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission's Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.

Open access tools for the genetics of disease - Many diseases have a genetic component, yet we lack the tools to study many of the genes behind diseases. This topic aims to develop a set of open access tools to facilitate the study around 1 000 of the 3 000 genes thought to be implicated in disease and that could be targeted by drugs. The results of the project will be made fully available to the scientific community by open access.

Optimising future obesity treatment - Obesity affects some 650 million people globally, placing them at greater risk of complications such as heart disease, diabetes and cancer to name a few. This topic aims to better understand obesity as a disease by identifying subgroups of people with obesity that will ultimately pave the way for better, more personalised prevention and lifestyle interventions, as well as treatments for obesity and its complications. The project will also focus on diabetes (both types 1 and 2) as examples of conditions that are influenced by obesity in a complex way.

Environmental impacts of medicines - Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). This topic will help to reduce the impact of medicines on the environment in three ways. Firstly, it will deliver tools to identify environmental risks associated with medicines under development. Secondly, it will prioritise which existing medicines (introduced before the ERA) should go through a tailored environmental assessment. Finally, it will create a publicly-available database to make environmental data on human medicinal products more transparent to all stakeholders.

Pierre Meulien, IMI Executive Director commented: "If we want to enjoy the benefits of the genomic revolution, we have to develop tools to study in detail the genes that influence our health. By taking an open access approach, the new topic launched as part of today's Call for proposals will maximise the impacts of its results by making it possible for researchers worldwide to access and use them in their own work."

For more information on IMI2 - Call 17, including the full Call text and details of how to apply, please visit:
http://www.imi.europa.eu/imi2-call-17

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

AI-Pathway Companion Prostate Cancer fro…

AI-Pathway Companion Prostate Cancer(2), a digital companion from Siemens Healthineers to support clinical decision-making, has recently received the CE mark for use in the clinical pathway of prostate cancer, the...

Philips Launches HealthSuite System of E…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the HealthSuite System of Engagement, an integrated, modular set of standards-based capabilities that support the development...

AI may Help Spot Newborns at Risk for Mo…

An artificial intelligence (AI) device that has been fast-tracked for approval by the Food and Drug Administration may help identify newborns at risk for aggressive posterior retinopathy of prematurity (AP-ROP)...

Best of Breed: Start with Data in Open P…

Better is attending this year's Digital Health Rewired conference and exhibition at Olympia London alongside Taunton and Somerset NHS Foundation Trust, which is using its open platform to develop an...

Highland Marketing is Sponsoring the Caf…

Highland Marketing will be returning to Digital Health Rewired this year, where it will be sponsoring the café that has been created with an expanded exhibition area. Digital Health Rewired launched...

International Scientific Symposium DigiH…

13 November 2020, Pfarrkirchen, Germany DigiHealthDay @DIT-ECRI is going to be a daylong action-packed event targeting primarily academia - from established researchers, to young scientists and students. Following the theme "How...

Siemens Healthineers Introduces Teamplay…

Siemens Healthineers announces market introduction of the teamplay digital health platform. With the teamplay digital health platform Siemens Healthineers paves the way for healthcare providers' digital transformation - facilitating easy...

Digital Heart Model will Help Predict Fu…

In recent times, researchers have increasing found that the power of computers and artificial intelligence is enabling more accurate diagnosis of a patient's current heart health and can provide an...

Fighting Hand Tremors: First comes AI, t…

Robots hold promise for a large number of people with neurological movement disorders severely affecting the quality of their lives. Now researchers have tapped artificial intelligence techniques to build an...